If Amarin investors' new plan is to ask companies on conference calls whether they have an interest in a making a deal, bravo. Amarin shares traded up nearly 10% intraday on the surprise disclosure during a shareholder call for Elan discussing other proposed purchases.

In this video, health-care analyst David Williamson discusses what this and the recent buyout of a competitor means for Amarin investors and what key catalyst is coming for the company before 2013 comes to a close.

David Williamson owns shares of Amarin. Follow David on Twitter: @MotleyDavid.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.